European Investment Bank

Orano is a leading global company based in Courbevoie, France, specializing in nuclear power and renewable energy solutions. The company offers a comprehensive range of services covering every stage of the nuclear fuel cycle, including reactor design, construction, and operational support. With a strong emphasis on safety and advanced technology, Orano is committed to supplying low-carbon power generation solutions. Additionally, it engages in renewable energy initiatives through partnerships aimed at developing high-tech solutions. As energy demand increases and the need for sustainable practices intensifies, Orano focuses on creating cleaner energy alternatives that contribute to reducing greenhouse gas emissions. The company aims to enhance transparency, coherence, and efficiency in its operations while preparing for the future energy landscape.

Nomagic, Inc. is a company based in Warsaw, Poland, specializing in robotic manipulation solutions for order fulfillment in e-commerce warehouses. By providing smart pick-and-place robotic systems, Nomagic enhances efficiency, flexibility, and reliability in the logistics process. Their technology automates repetitive tasks, reduces fulfillment costs, and addresses labor shortages, allowing warehouses to operate seamlessly around the clock. The company's robots have already been implemented on packing lines at Cdiscount, a leading French e-commerce platform. Utilizing artificial intelligence, Nomagic's systems continuously learn and adapt to changing conditions, improving the agility of warehouse operations and ensuring reliable delivery of goods.

Median Technologies SA specializes in the development and marketing of software products and platforms for medical image analysis, primarily focusing on oncology. Founded in 2002 and headquartered in Valbonne, France, the company operates internationally, offering solutions that enhance the diagnosis and treatment of cancer patients. Its key products include iBiopsy, an imaging platform that utilizes AI for biomarker identification, and iSee, which supports image analysis and management in clinical trials. Additionally, Median provides a range of imaging contract research services, including study startup, data management, and scientific consulting to optimize clinical trials. The company collaborates with a contract research organization and Canon to enhance its imaging technologies and services, aiming to improve patient care and streamline drug development processes.

Cellectis S.A. is a clinical-stage biotechnological company based in Paris, France, focused on developing innovative immuno-oncology therapies using gene-edited T-cells. The company specializes in allogeneic Chimeric Antigen Receptor T-cell (CAR-T) products, with a portfolio that includes several product candidates targeting various hematologic malignancies. Notable candidates include UCART19, aimed at treating CD19-expressing hematologic cancers such as acute lymphoblastic leukemia; UCART123 for acute myeloid leukemia; and UCARTCS1 and ALLO-715 for multiple myeloma. In addition to its therapeutic efforts, Cellectis also produces high oleic soybean oil and other soybean products, as well as fiber wheat. The company collaborates with various strategic partners, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to advance its mission of eradicating cancer through cutting-edge gene-editing technologies.

Fab'entech, founded in 2009 in Lyon, France, is a biopharmaceutical company that specializes in developing and commercializing innovative passive immunotherapeutic solutions. The company focuses on specific polyclonal immunoglobulins [F(ab’)₂] to address emerging infectious diseases and certain drug intoxications. By utilizing highly purified fragments of horse-specific polyclonal immunoglobulins, Fab'entech provides healthcare institutions with effective treatments for emergency situations. As a member of the LyonBiopôle cluster, the company is positioned within a network that fosters biotechnological advancements in the region.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Endesa is an electric utility company headquartered in Madrid, Spain, that generates, distributes, and supplies electricity primarily in Spain and Portugal. Founded in 1944, the company has an installed generation capacity of 22 gigawatts, utilizing a diverse mix of energy sources, including hydroelectric, nuclear, coal, natural gas, oil, solar, and wind. Endesa serves approximately 11.2 million customers and employs over 10,000 people. In addition to its core electricity services, Endesa operates in the natural gas sector and provides energy-related services, emphasizing a commitment to sustainability and technological innovation to address current and future energy challenges. The company also supplies gas to retail and business customers in Spain and France.

SiPearl is a French semiconductor company established in 2019, headquartered in Maisons-Laffitte, Île-de-France, with research and development centers located in France, Germany, and Spain. The company specializes in the design of high-performance, low-power microprocessors intended for exascale supercomputers, aligning its product development with the European Union’s technological goals. Its first microprocessor range, Rhea, is set for commercialization in early 2024 and is based on the Arm Neoverse V1 architecture. SiPearl is committed to manufacturing Rhea using advanced processes from TSMC, ensuring state-of-the-art performance. The microprocessors are aimed at a variety of applications, including computing, artificial intelligence, medical research, climate change mitigation, and energy management, serving scientific researchers and major players in the IT, electronics, and automotive sectors.

Reden Solar specializes in the development, financing, construction, and operation of solar photovoltaic power plants across Europe and Latin America. With an installed portfolio of 762 megawatts and an additional 15 gigawatts under development, the company primarily focuses on markets in France and Spain, while also expanding its operations in Greece and Italy. Reden Solar provides a variety of photovoltaic solutions, including agricultural greenhouses, ground-mounted systems, shelters, and rooftop installations, aimed at promoting sustainable energy production and contributing to environmental conservation.

Orange is a global telecommunications company, founded in 1991 and headquartered in Paris, France. It operates in 30 countries across Europe and Africa, providing mobile and internet services to consumers, and corporate telecommunication services worldwide. Through its business arm, Orange Business Services, it caters to large corporates, local authorities, and SMEs, offering a comprehensive range of voice and data, IT, and integrated services. Additionally, Orange supports digital innovation through its international network of startup accelerators, Orange Fabs, which provides resources and expertise to startups in the digital space.

AB Science is a France-based pharmaceutical company founded in 2001 by a team of researchers, clinicians, and entrepreneurs. It specializes in the research, discovery, development, and marketing of protein kinase inhibitors, focusing on targeted therapies using tyrosine kinase inhibitors. The company aims to address significant unmet medical needs in various fields, including cancer, chronic inflammatory diseases, neurological degenerative disorders, and central nervous system diseases. AB Science is committed to innovating and developing new drugs that can significantly improve the lives of patients and enhance treatment outcomes in both human and veterinary medicine.

Cellectis S.A. is a clinical-stage biotechnological company based in Paris, France, focused on developing innovative immuno-oncology therapies using gene-edited T-cells. The company specializes in allogeneic Chimeric Antigen Receptor T-cell (CAR-T) products, with a portfolio that includes several product candidates targeting various hematologic malignancies. Notable candidates include UCART19, aimed at treating CD19-expressing hematologic cancers such as acute lymphoblastic leukemia; UCART123 for acute myeloid leukemia; and UCARTCS1 and ALLO-715 for multiple myeloma. In addition to its therapeutic efforts, Cellectis also produces high oleic soybean oil and other soybean products, as well as fiber wheat. The company collaborates with various strategic partners, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to advance its mission of eradicating cancer through cutting-edge gene-editing technologies.

AB Science is a France-based pharmaceutical company founded in 2001 by a team of researchers, clinicians, and entrepreneurs. It specializes in the research, discovery, development, and marketing of protein kinase inhibitors, focusing on targeted therapies using tyrosine kinase inhibitors. The company aims to address significant unmet medical needs in various fields, including cancer, chronic inflammatory diseases, neurological degenerative disorders, and central nervous system diseases. AB Science is committed to innovating and developing new drugs that can significantly improve the lives of patients and enhance treatment outcomes in both human and veterinary medicine.

Advicenne is a late-stage biopharmaceutical company founded in 2007 and headquartered in Nîmes, France. The company focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly targeting orphan renal diseases and niche neurology indications. Its lead drug candidate, ADV7103, is undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the lives of patients from early childhood through adulthood.

OVH APAC is a leading cloud provider known for its innovative and cost-effective solutions tailored for a diverse clientele, ranging from startups to large enterprises. Founded in 1999 by Octave Klaba and based in France, OVH offers a comprehensive portfolio of services, including web hosting, dedicated servers, cloud solutions, domain registration, and VOIP telephony. The company distinguishes itself through its proprietary global fiber-optic network and green data centers, which enable optimal performance and reliability. With a commitment to research and development and complete control over its supply chain, OVH delivers high-quality products and exceptional customer service. Additionally, OVH has established a strong partnership with VMware, integrating advanced software solutions to enhance network performance and streamline service delivery for its customers. As a result, OVH is recognized as one of the top internet hosting companies globally, serving millions of customers with cutting-edge technology and expertise.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Prophesee SA, founded in 2014 and based in Paris, France, specializes in advanced machine vision sensors and systems through its innovative neuromorphic vision technology. Originally known as Chronocam SAS, the company rebranded in 2018 to reflect its pioneering approach to computer vision, which mimics the human eye and brain by detecting essential motion information rather than capturing a series of images. This unique Metavision® method enables Prophesee to achieve exceptional performance metrics, including high-speed time resolution, dynamic range, and significant reductions in data volume and power consumption. Its technology caters to a diverse range of industries, including biomedical, gaming, industrial automation, mobile devices, robotics, security, and automotive applications. Prophesee's team of over 100 engineers holds more than 50 international patents and has established a global presence with offices in cities such as Grenoble, Shanghai, Tokyo, and Silicon Valley, supported by a network of prominent investors.

Nomagic, Inc. is a company based in Warsaw, Poland, specializing in robotic manipulation solutions for order fulfillment in e-commerce warehouses. By providing smart pick-and-place robotic systems, Nomagic enhances efficiency, flexibility, and reliability in the logistics process. Their technology automates repetitive tasks, reduces fulfillment costs, and addresses labor shortages, allowing warehouses to operate seamlessly around the clock. The company's robots have already been implemented on packing lines at Cdiscount, a leading French e-commerce platform. Utilizing artificial intelligence, Nomagic's systems continuously learn and adapt to changing conditions, improving the agility of warehouse operations and ensuring reliable delivery of goods.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Kayrros is a leading advanced data analytics company that specializes in providing actionable insights for the global energy market. With a team of over 100 employees from more than 15 nationalities, Kayrros operates from its headquarters in Paris and has additional offices in Houston, London, New York, and Singapore. The company integrates alternative and market data to create unique product offerings that enhance decision-making across the energy sector. Its platform focuses on environmental intelligence and asset observation, delivering critical insights related to greenhouse gas reduction, ecosystem protection, and energy transition management. Kayrros aims to support governments, companies, and investment markets in assessing the climate impact of energy and industrial activities, thereby enabling faster and more informed decisions. The company’s solutions are designed to be scalable and continuously expand to include new geographic regions and data sources, enhancing transparency in energy markets worldwide.

Priothera Ltd is a clinical-stage company based in Dublin, Ireland, with an additional location in Saint Louis, France. It specializes in the development of orally applied sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's primary focus is on its lead product, mocravimod, which is designed to enhance the curative potential of allogeneic haematopoietic stem cell transplants. By reducing the egress of T cell subsets from lymphatic tissues, Priothera's modulators aim to provide dual inhibition of graft versus host disease while also promoting graft versus leukemia effects, ultimately improving patient outcomes in this challenging area of medicine.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

Bouygues Telecom is a prominent telecommunications operator in France, offering a wide range of services that include mobile, fixed-line, television, internet, and cloud computing. The company serves approximately 11.1 million mobile customers and 2.1 million fixed broadband customers, including over 1.5 million professional and corporate clients. Renowned for its innovative approach, Bouygues Telecom has introduced several pioneering products, such as the first unlimited call plans, fixed-mobile convergence offers for corporate customers, and the quadruple play solution known as ideo. The company also launched B&YOU, a web-only offer that revolutionized mobile telephony. With a mobile network that covers 99% of the population and a rapidly expanding 4G network, Bouygues Telecom is committed to enhancing customer experience through its dedicated team of over 9,000 employees and a robust customer service framework that includes 2,000 advisers and 2,500 sales staff. The company's focus on innovation and customer satisfaction positions it as a key player in the French telecommunications market.

Advicenne is a late-stage biopharmaceutical company founded in 2007 and headquartered in Nîmes, France. The company focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly targeting orphan renal diseases and niche neurology indications. Its lead drug candidate, ADV7103, is undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the lives of patients from early childhood through adulthood.

Median Technologies SA specializes in the development and marketing of software products and platforms for medical image analysis, primarily focusing on oncology. Founded in 2002 and headquartered in Valbonne, France, the company operates internationally, offering solutions that enhance the diagnosis and treatment of cancer patients. Its key products include iBiopsy, an imaging platform that utilizes AI for biomarker identification, and iSee, which supports image analysis and management in clinical trials. Additionally, Median provides a range of imaging contract research services, including study startup, data management, and scientific consulting to optimize clinical trials. The company collaborates with a contract research organization and Canon to enhance its imaging technologies and services, aiming to improve patient care and streamline drug development processes.

Orange is a global telecommunications company, founded in 1991 and headquartered in Paris, France. It operates in 30 countries across Europe and Africa, providing mobile and internet services to consumers, and corporate telecommunication services worldwide. Through its business arm, Orange Business Services, it caters to large corporates, local authorities, and SMEs, offering a comprehensive range of voice and data, IT, and integrated services. Additionally, Orange supports digital innovation through its international network of startup accelerators, Orange Fabs, which provides resources and expertise to startups in the digital space.

Prophesee SA, founded in 2014 and based in Paris, France, specializes in advanced machine vision sensors and systems through its innovative neuromorphic vision technology. Originally known as Chronocam SAS, the company rebranded in 2018 to reflect its pioneering approach to computer vision, which mimics the human eye and brain by detecting essential motion information rather than capturing a series of images. This unique Metavision® method enables Prophesee to achieve exceptional performance metrics, including high-speed time resolution, dynamic range, and significant reductions in data volume and power consumption. Its technology caters to a diverse range of industries, including biomedical, gaming, industrial automation, mobile devices, robotics, security, and automotive applications. Prophesee's team of over 100 engineers holds more than 50 international patents and has established a global presence with offices in cities such as Grenoble, Shanghai, Tokyo, and Silicon Valley, supported by a network of prominent investors.

FlixBus, operated by FlixMobility, is a notable provider of intercity travel, focusing on affordable, convenient, and environmentally-friendly transportation solutions. Since its inception in 2013, the company has established Europe's largest long-distance bus network and introduced green long-distance trains in 2018, alongside a pilot for all-electric buses in Germany and France. The platform offers travelers a sustainable alternative to private transportation, featuring amenities such as free WiFi, flexible online booking, and innovative ticketing systems. FlixBus also expanded its services to the United States in 2018, bringing its unique travel model to a broader audience. By collaborating with regional bus partners and private train companies, FlixMobility combines technological innovation with traditional transportation expertise, positioning itself as a leader in the evolving mobility landscape. As a result, FlixBus has transformed the travel experience for over 100 million people across Europe and the United States while contributing to job creation in the mobility sector.

Mobidiag is a Finnish-French biotechnology company that focuses on developing and marketing innovative molecular diagnostic solutions aimed at detecting gastrointestinal infections, antimicrobial resistance, healthcare-associated infections, respiratory infections, and sepsis. Utilizing established qPCR and microarray technologies, Mobidiag provides a wide array of fast, reliable, and cost-effective diagnostic tests and automated platforms suitable for laboratories of various sizes. Their offerings enable the detection of a broad spectrum of clinically relevant bacteria, parasites, viruses, and antibiotic resistance markers, thereby facilitating quicker diagnosis and treatment in hospitals, laboratories, and clinics.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

MotorK is a software as a service (SaaS) provider focused on the automotive retail industry in the EMEA region, employing over 400 staff across eleven offices in eight countries, including Italy, Spain, France, Germany, Portugal, the UK, Belgium, and Israel. The company specializes in developing digital sales and marketing solutions that enhance customer experience for car manufacturers and dealers. MotorK offers a comprehensive suite of integrated digital products and services, including platforms for traffic acquisition, inventory management, sales operations, and promotional campaigns. Key products include WebSparK, a web module known for its technical and design excellence, and StockSparK, a stock management tool that aggregates and enhances inventory visibility for potential buyers. With a strong emphasis on innovation, MotorK boasts one of the largest research and development teams in the European automotive digital sales and marketing sector.

Mobidiag is a Finnish-French biotechnology company that focuses on developing and marketing innovative molecular diagnostic solutions aimed at detecting gastrointestinal infections, antimicrobial resistance, healthcare-associated infections, respiratory infections, and sepsis. Utilizing established qPCR and microarray technologies, Mobidiag provides a wide array of fast, reliable, and cost-effective diagnostic tests and automated platforms suitable for laboratories of various sizes. Their offerings enable the detection of a broad spectrum of clinically relevant bacteria, parasites, viruses, and antibiotic resistance markers, thereby facilitating quicker diagnosis and treatment in hospitals, laboratories, and clinics.

Navya SA is a prominent French company specializing in autonomous vehicle technology and smart shared mobility solutions. Founded in 2014 and headquartered in Villeurbanne, France, Navya develops, manufactures, and services a range of driverless electric vehicles, including autonomous shuttles and cabs. The company primarily caters to municipalities, industrial sites, universities, theme parks, and airports, and its products are available in the United States, EMEA, and Asia-Pacific regions. Navya has been a pioneer in the autonomous mobility sector, launching its first shuttle, the AUTONOM®SHUTTLE, in 2015, with over 100 units produced and sold in multiple countries. The AUTONOM®CAB, introduced in 2017, is set to undergo road tests soon. With a workforce of more than 200 employees in France and the United States, Navya combines advanced robotic and digital technologies to deliver innovative mobility solutions.

October is a pan-European lending platform that aims to empower businesses by simplifying access to funding. Founded in France in 2014 under the name Lendix, the company emerged following regulatory changes that disrupted traditional banking practices. With offices in France, Spain, Italy, and the Netherlands, October operates an online marketplace that connects private investors with enterprises of various sizes. This platform allows investors to finance businesses directly, offering fully disclosed terms and facilitating a streamlined investment process. Institutional lenders complement individual contributions, ensuring borrowers benefit from high success rates and quick processing times. October's mission is to democratize finance, providing a secure and efficient way for individuals to invest in the real economy.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Forsee Power SAS, founded in 2007 and based in Ivry-sur-Seine, France, specializes in the design and manufacture of smart lithium-ion battery systems. The company serves various sectors, including electric transportation, portable and mobile equipment, and energy storage. Its product offerings include modular battery systems for electric and hybrid vehicles, trams, electric trains, buses, trucks, and marine applications such as ships and ferries. Additionally, Forsee Power provides power systems for mobile and connected devices across numerous fields, including medical equipment, electric scooters, and robotics. The company's focus on innovation and customer satisfaction aims to facilitate a sustainable energy transition and enhance the performance of smart mobility and life devices globally.

SunPartner Technologies, founded in 2008 and based in Rousset, France, specializes in the development and commercialization of advanced photovoltaic technologies. The company focuses on integrating solar solutions into various applications, including mobile devices and infrastructure. Its notable products include Wysips Crystal, an ultra-thin and transparent photovoltaic material designed for smartphones and smartwatches, and Wysips Graphics, which incorporates solar cells into connected devices. Additionally, SunPartner offers Wysips Reflect for reflective screens and Wysips Cameleon for signage and billboards. The company also explores innovations in communication technologies, such as Light-Fidelity, which utilizes visible light for data transmission, applicable in smart cities and location-based services. Through its diverse portfolio, SunPartner aims to enhance energy autonomy and promote sustainable energy solutions in multiple sectors.

Electro Power Systems operates in the sustainable energy sector, focusing on hybrid-storage solutions and microgrids that convert intermittent renewable energy into a reliable power source. Headquartered in Paris, with research, development, and manufacturing facilities in Italy, the company has developed innovative hybrid energy storage technologies, supported by 125 patents and over a decade of research and development. These solutions are designed to stabilize electrical grids with high levels of renewable energy integration in developed countries and provide cost-effective off-grid power in emerging economies without relying on subsidies. Electro Power Systems has successfully implemented and is commissioning 36 large-scale projects, including off-grid hybrid systems and grid support systems, totaling over 47 MWh of capacity across 21 countries, serving more than 165,000 customers daily.

Mobidiag is a Finnish-French biotechnology company that focuses on developing and marketing innovative molecular diagnostic solutions aimed at detecting gastrointestinal infections, antimicrobial resistance, healthcare-associated infections, respiratory infections, and sepsis. Utilizing established qPCR and microarray technologies, Mobidiag provides a wide array of fast, reliable, and cost-effective diagnostic tests and automated platforms suitable for laboratories of various sizes. Their offerings enable the detection of a broad spectrum of clinically relevant bacteria, parasites, viruses, and antibiotic resistance markers, thereby facilitating quicker diagnosis and treatment in hospitals, laboratories, and clinics.